Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
10.45 USD -1.60% Intraday chart for Zentalis Pharmaceuticals, Inc. -8.33% -31.02%
May. 29 Zentalis Pharmaceuticals, Inc. Announces Appointment of Luke Walker, M.D., to Board of Directors and Audit Committee of the Board CI
May. 24 Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial MT

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Number of employees: 124

Managers

Managers TitleAgeSince
Kimberly Blackwell CEO
 Chief Executive Officer 55 20-06-30
Cam Gallagher FOU
 Founder 54 14-12-22
Mark Lackner CTO
 Chief Tech/Sci/R&D Officer 56 22-10-16
Diana Hausman CTO
 Chief Tech/Sci/R&D Officer 61 23-05-07
Kyle Rasbach IRC
 Investor Relations Contact - Jan. 18
Kimberly Freeman PRN
 Corporate Officer/Principal - 23-07-31
Alexandra Roy
- -
Andrea Paul LAW
 General Counsel 43 22-07-31
Meena Rao LAW
 General Counsel - -
Dimitris Voliotis PRN
 Corporate Officer/Principal 61 20-02-29

Members of the board

Members of the board TitleAgeSince
Cam Gallagher FOU
 Founder 54 14-12-22
Diana Hausman CTO
 Chief Tech/Sci/R&D Officer 61 23-05-07
Karan Takhar BRD
 Director/Board Member 32 17-11-30
Jan Skvarka BRD
 Director/Board Member 57 22-09-11
Enoch K. Kariuki BRD
 Director/Board Member 42 21-02-08
David Johnson CHM
 Chairman 59 20-01-08
Kimberly Blackwell CEO
 Chief Executive Officer 55 20-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 71,013,233 68,311,931 ( 96.20 %) 0 96.20 %

Shareholders

NameEquities%Valuation
Matrix Capital Management Co. LP
19.66 %
13,959,973 19.66 % 166 M $
Eventide Asset Management LLC
16.30 %
11,574,821 16.30 % 138 M $
Fidelity Management & Research Co. LLC
14.99 %
10,644,024 14.99 % 126 M $
BlackRock Advisors LLC
6.203 %
4,404,747 6.203 % 52 M $
Vanguard Fiduciary Trust Co.
6.194 %
4,398,625 6.194 % 52 M $
Citadel Securities GP LLC
5.425 %
3,852,429 5.425 % 46 M $
STATE STREET CORPORATION
5.331 %
3,785,652 5.331 % 45 M $
T. Rowe Price International Ltd.
4.914 %
3,489,709 4.914 % 41 M $
T. Rowe Price Investment Management, Inc.
4.674 %
3,319,086 4.674 % 39 M $
Capital Research & Management Co. (International Investors)
3.971 %
2,819,664 3.971 % 33 M $

Company contact information

Zentalis Pharmaceuticals, Inc.

1359 Broadway Suite 801

10018, New York

+

http://www.zentalis.com
address Zentalis Pharmaceuticals, Inc.(ZNTL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.62 USD
Average target price
33.4 USD
Spread / Average Target
+214.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZENTALIS PHARMACEUTICALS, INC. Stock Zentalis Pharmaceuticals, Inc.
-32.21% 754M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+19.17% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.86% 108B
BIONTECH SE Stock BioNTech SE
-7.60% 24.21B
ARGENX SE Stock argenx SE
+2.07% 22.78B
GENMAB A/S Stock Genmab A/S
-10.79% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.76% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.66% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.81% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. Company Zentalis Pharmaceuticals, Inc.